



1617

\$

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/045,596
Filing Date	October 18, 2001
First Named Inventor	Paul A. Price
Group Art Unit	Theodore J. Criares
Examiner Name	1617
Attorney Docket Number	407T-893910US

Total Number of Pages in This Submission **5**

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	receipt acknowledgment postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Tom Hunter, Reg. No. 38,498, Quine Intellectual Property Law Group, P.C.		
Signature			
Date	July 9, 2003		

RECEIVED
JUL 17 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Amelia Groth		
Signature		Date	July 9, 2003



#15
7/20/03
[Signature]

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents
PO Box 1450, Alexandria, VA 22313-1450, on July 9, 2003
QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By: *[Signature]*
Amelia Groth

Atty Docket No: 407T-893910US
Client Ref: 2002-115-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PAUL A. PRICE

Examiner: Theodore J. Criares

Application No.: **10/045,596**

Art Unit: 1617

Filed: **10/18/2001**

For: **A FETUIN-MGP-MINERAL
COMPLEX IN SERUM**

**RESPONSE TO RESTRICTION
REQUIREMENT**

Assistant Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450
Sir:

This paper is filed in response to the Office Action dated March 25, 2003 containing a Restriction Requirement. The following documents are enclosed herewith:

- 1) A petition to extend the period of response for three months.

REMARKS

In the March 25, 2003 Office Action the Examiner required restriction to one of the following groups under 35 U.S.C. §121:

Group I: Claims 1-12, drawn to a method of determining the risk for calcification of arteries and other tissues in mammals;

Group II: Claims 13-21, drawn to a method of screening for an agent that reduces or ameliorates one or more symptoms of the calcification of arteries and other soft tissues;

Group III: Claims 22-31, drawn to a method of monitoring the efficacy of a treatment for one or more symptoms of calcification of arteries and other soft tissues in a mammal;

Group IV: Claims 33-43, drawn to a method of determining the risk for atherosclerosis in a mammal;